687 related articles for article (PubMed ID: 26670557)
21. FXR activation improves myocardial fatty acid metabolism in a rodent model of obesity-driven cardiotoxicity.
Mencarelli A; Cipriani S; Renga B; D'Amore C; Palladino G; Distrutti E; Baldelli F; Fiorucci S
Nutr Metab Cardiovasc Dis; 2013 Feb; 23(2):94-101. PubMed ID: 21924881
[TBL] [Abstract][Full Text] [Related]
22. Differential activation of the human farnesoid X receptor depends on the pattern of expressed isoforms and the bile acid pool composition.
Vaquero J; Monte MJ; Dominguez M; Muntané J; Marin JJ
Biochem Pharmacol; 2013 Oct; 86(7):926-39. PubMed ID: 23928191
[TBL] [Abstract][Full Text] [Related]
23. Gut microbiota regulates bile acid metabolism by reducing the levels of tauro-beta-muricholic acid, a naturally occurring FXR antagonist.
Sayin SI; Wahlström A; Felin J; Jäntti S; Marschall HU; Bamberg K; Angelin B; Hyötyläinen T; Orešič M; Bäckhed F
Cell Metab; 2013 Feb; 17(2):225-35. PubMed ID: 23395169
[TBL] [Abstract][Full Text] [Related]
24. FXR Primes the Liver for Intestinal FGF15 Signaling by Transient Induction of β-Klotho.
Fu T; Kim YC; Byun S; Kim DH; Seok S; Suino-Powell K; Xu HE; Kemper B; Kemper JK
Mol Endocrinol; 2016 Jan; 30(1):92-103. PubMed ID: 26505219
[TBL] [Abstract][Full Text] [Related]
25. FXR-dependent reduction of hepatic steatosis in a bile salt deficient mouse model.
Kunne C; Acco A; Duijst S; de Waart DR; Paulusma CC; Gaemers I; Oude Elferink RP
Biochim Biophys Acta; 2014 May; 1842(5):739-46. PubMed ID: 24548803
[TBL] [Abstract][Full Text] [Related]
26. Relevance of FXR-p62/SQSTM1 pathway for survival and protection of mouse hepatocytes and liver, especially with steatosis.
Haga S; Yimin ; Ozaki M
BMC Gastroenterol; 2017 Jan; 17(1):9. PubMed ID: 28086800
[TBL] [Abstract][Full Text] [Related]
27. Ursodeoxycholic Acid Suppresses Lipogenesis in Mouse Liver: Possible Role of the Decrease in β-Muricholic Acid, a Farnesoid X Receptor Antagonist.
Fujita K; Iguchi Y; Une M; Watanabe S
Lipids; 2017 Apr; 52(4):335-344. PubMed ID: 28315136
[TBL] [Abstract][Full Text] [Related]
28. Farnesoid X receptor (FXR) agonist ameliorates systemic insulin resistance, dysregulation of lipid metabolism, and alterations of various organs in a type 2 diabetic kidney animal model.
Han SY; Song HK; Cha JJ; Han JY; Kang YS; Cha DR
Acta Diabetol; 2021 Apr; 58(4):495-503. PubMed ID: 33399988
[TBL] [Abstract][Full Text] [Related]
29. INT-767 improves histopathological features in a diet-induced
Roth JD; Feigh M; Veidal SS; Fensholdt LK; Rigbolt KT; Hansen HH; Chen LC; Petitjean M; Friley W; Vrang N; Jelsing J; Young M
World J Gastroenterol; 2018 Jan; 24(2):195-210. PubMed ID: 29375205
[TBL] [Abstract][Full Text] [Related]
30. Farnesoid X receptor deficiency improves glucose homeostasis in mouse models of obesity.
Prawitt J; Abdelkarim M; Stroeve JH; Popescu I; Duez H; Velagapudi VR; Dumont J; Bouchaert E; van Dijk TH; Lucas A; Dorchies E; Daoudi M; Lestavel S; Gonzalez FJ; Oresic M; Cariou B; Kuipers F; Caron S; Staels B
Diabetes; 2011 Jul; 60(7):1861-71. PubMed ID: 21593203
[TBL] [Abstract][Full Text] [Related]
31. Identification of isotschimgine as a novel farnesoid X receptor agonist with potency for the treatment of obesity in mice.
Li Y; Chen H; Ke Z; Huang J; Huang L; Yang B; Fan S; Huang C
Biochem Biophys Res Commun; 2020 Jan; 521(3):639-645. PubMed ID: 31679693
[TBL] [Abstract][Full Text] [Related]
32. Bile acid signaling through FXR induces intracellular adhesion molecule-1 expression in mouse liver and human hepatocytes.
Qin P; Borges-Marcucci LA; Evans MJ; Harnish DC
Am J Physiol Gastrointest Liver Physiol; 2005 Aug; 289(2):G267-73. PubMed ID: 15817812
[TBL] [Abstract][Full Text] [Related]
33. Lowering bile acid pool size with a synthetic farnesoid X receptor (FXR) agonist induces obesity and diabetes through reduced energy expenditure.
Watanabe M; Horai Y; Houten SM; Morimoto K; Sugizaki T; Arita E; Mataki C; Sato H; Tanigawara Y; Schoonjans K; Itoh H; Auwerx J
J Biol Chem; 2011 Jul; 286(30):26913-20. PubMed ID: 21632533
[TBL] [Abstract][Full Text] [Related]
34. Intestinal FXR agonism promotes adipose tissue browning and reduces obesity and insulin resistance.
Fang S; Suh JM; Reilly SM; Yu E; Osborn O; Lackey D; Yoshihara E; Perino A; Jacinto S; Lukasheva Y; Atkins AR; Khvat A; Schnabl B; Yu RT; Brenner DA; Coulter S; Liddle C; Schoonjans K; Olefsky JM; Saltiel AR; Downes M; Evans RM
Nat Med; 2015 Feb; 21(2):159-65. PubMed ID: 25559344
[TBL] [Abstract][Full Text] [Related]
35. The nuclear receptor FXR is expressed in pancreatic beta-cells and protects human islets from lipotoxicity.
Popescu IR; Helleboid-Chapman A; Lucas A; Vandewalle B; Dumont J; Bouchaert E; Derudas B; Kerr-Conte J; Caron S; Pattou F; Staels B
FEBS Lett; 2010 Jul; 584(13):2845-51. PubMed ID: 20447400
[TBL] [Abstract][Full Text] [Related]
36. Activation of farnesoid X receptor attenuates hepatic injury in a murine model of alcoholic liver disease.
Wu W; Zhu B; Peng X; Zhou M; Jia D; Gu J
Biochem Biophys Res Commun; 2014 Jan; 443(1):68-73. PubMed ID: 24269813
[TBL] [Abstract][Full Text] [Related]
37. The Hypoglycemic Effect of Berberine and Berberrubine Involves Modulation of Intestinal Farnesoid X Receptor Signaling Pathway and Inhibition of Hepatic Gluconeogenesis.
Sun R; Kong B; Yang N; Cao B; Feng D; Yu X; Ge C; Feng S; Fei F; Huang J; Lu Z; Xie Y; Yang CS; Guo GL; Wang G; Aa J
Drug Metab Dispos; 2021 Mar; 49(3):276-286. PubMed ID: 33376148
[TBL] [Abstract][Full Text] [Related]
38. Dietary fat and gut microbiota interactions determine diet-induced obesity in mice.
Kübeck R; Bonet-Ripoll C; Hoffmann C; Walker A; Müller VM; Schüppel VL; Lagkouvardos I; Scholz B; Engel KH; Daniel H; Schmitt-Kopplin P; Haller D; Clavel T; Klingenspor M
Mol Metab; 2016 Dec; 5(12):1162-1174. PubMed ID: 27900259
[TBL] [Abstract][Full Text] [Related]
39. MicroRNA-194 inhibition improves dietary-induced non-alcoholic fatty liver disease in mice through targeting on FXR.
Nie H; Song C; Wang D; Cui S; Ren T; Cao Z; Liu Q; Chen Z; Chen X; Zhou Y
Biochim Biophys Acta Mol Basis Dis; 2017 Dec; 1863(12):3087-3094. PubMed ID: 28951211
[TBL] [Abstract][Full Text] [Related]
40. Bile acid retention and activation of endogenous hepatic farnesoid-X-receptor in the pathogenesis of fatty liver disease in ob/ob-mice.
Martin IV; Schmitt J; Minkenberg A; Mertens JC; Stieger B; Mullhaupt B; Geier A
Biol Chem; 2010 Dec; 391(12):1441-9. PubMed ID: 20868235
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
